Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Bioindustry ethics [[electronic resource] /] / David L. Finegold ... [et al.]
| Bioindustry ethics [[electronic resource] /] / David L. Finegold ... [et al.] |
| Pubbl/distr/stampa | Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 |
| Descrizione fisica | 1 online resource (384 p.) |
| Disciplina | 174/.96606 |
| Altri autori (Persone) | FinegoldDavid |
| Soggetto topico |
Biotechnology industries - Moral and ethical aspects
Pharmaceutical industry - Moral and ethical aspects Business ethics - Moral and ethical aspects |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-00533-9
9786611005337 0-08-049251-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BIOINDUSTRY ETHICS; BIOINDUSTRY ETHICS; Contents; Research Team; Preface; Acknowledgments; Introduction; ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES; WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS?; ETHICISTS AND THE BIOSCIENCE INDUSTRY; A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS; STRUCTURE OF THE BOOK; Merck: Staying the Course; INTRODUCTION; FOCUSING ON PATIENTS AND THE LONG TERM; ETHICS RESOURCE CENTERS; INTERNAL ETHICAL PRACTICES; ASSESSING THE IMPACT; BENEFITS OF AN ETHICAL APPROACH; ETHICAL ISSUES; DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY
CLINICAL TRIALS AND PUBLICATION OF RESULTSWHAT DRUGS TO DEVELOP; CHALLENGES FOR THE FUTURE; Genzyme: Putting Patients First; INTRODUCTION; PUTTING THE PATIENT FIRST: GENZYMEÌS APPROACH TO ETHICAL ISSUES; ETHICAL ISSUES; ETHICAL MECHANISMS; SUSTAINING THE GENZYME CULTURE; CONCLUSION; Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values; INTRODUCTION; MILLENNIUM PHARMACEUTICALS INC.; INSTITUTIONALIZING CORE VALUES AND ETHICS; ETHICS EDUCATION PROGRAMS; IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS; PRESERVING A FOCUS ON CORE VALUES; THE FUTURE Maxim Pharmaceuticals (A): Internal and External DialoguesAN UNUSUAL BIOTECH LEADER; THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY; COMPANY HISTORY; EMBEDDING CORE VALUES; MECHANISMS FOR EMBEDDING CORE VALUES; BUILDING A SUCCESSFUL GLOBAL BOARD; ANNUAL STRATEGIC RETREAT; DEALING WITH ETHICAL ISSUES; MAXIM PHARMACEUTICALS (B); Diversa Inc.: Ethical Issues in Bioprospecting Partnerships; FROM BIOPIRACY TO BIOPROSPECTING; THE COMPANY; THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS; DIVERSAÌS BIODIVERSITY COLLABORATIONS; PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS ETHICAL DECISION MAKINGTOWARD THE FUTURE; DIVERSA INC. (B); DIVERSA INC. (C); DIVERSA INC. (D); Pipeline Biotech A/S: Competing Regulatory Regimes for Laboratory Animal Experiments; INTRODUCTION; COMPANY HISTORY; BUSINESS MODEL AND ETHICAL APPROACH; EMPOWERING THE WORKFORCE; ETHICAL ISSUES AT PIPELINE; CONCLUSION; TGN Biotech: A Start-Up with Ethical Roots; WHAT NOW?; TGN BIOTECH; TGNÌS MARKET; SEMENESISTM; WHY PIGS AND WHY SEMEN?; THE ETHICAL ISSUES; MECHANISMS FOR A TRANSPARENT PROCESS; FUTURE POSSIBILITIES; WHAT NEXT?; Interleukin Genetics and Alticor: An Unlikely Partnership; INTRODUCTION COMPANY ORIGINSEXPLORING THE ETHICS OF GENETIC TESTING; FAILED EFFORTS TO BUILD A PERSONALIZED MEDICINE BUSINESS; PUTTING ETHICS EXPERTS IN CHARGE; APPROACH TO ETHICAL ISSUES; PROPOSED ALTICOR DEAL; INTERLEUKIN GENETICS AND ALTICOR: AN UNUSUAL PARTNERSHIP; CREATING AN ETHICAL APPROACH TO NUTRIGENOMICS; Sciona Ltd.: A Pioneer in Nutrigenomics: The Path to Consumer Acceptance; INTRODUCTION; BACKGROUND; PRODUCT LAUNCH; ETHICAL CONSIDERATIONS; THE CASE FOR ETHICS; APPLICATION TO THE HUMAN GENETICS COMMISSION; PUBLIC OPPOSITION; RESULTS; THE HGC RECOMMENDATIONS; TOWARD THE FUTURE Affymetrix, Inc.: Using Corporate Ethics Advice |
| Record Nr. | UNINA-9910458955503321 |
| Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bioindustry ethics [[electronic resource] /] / David L. Finegold ... [et al.]
| Bioindustry ethics [[electronic resource] /] / David L. Finegold ... [et al.] |
| Pubbl/distr/stampa | Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 |
| Descrizione fisica | 1 online resource (384 p.) |
| Disciplina | 174/.96606 |
| Altri autori (Persone) | FinegoldDavid |
| Soggetto topico |
Biotechnology industries - Moral and ethical aspects
Pharmaceutical industry - Moral and ethical aspects Business ethics - Moral and ethical aspects |
| ISBN |
1-281-00533-9
9786611005337 0-08-049251-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BIOINDUSTRY ETHICS; BIOINDUSTRY ETHICS; Contents; Research Team; Preface; Acknowledgments; Introduction; ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES; WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS?; ETHICISTS AND THE BIOSCIENCE INDUSTRY; A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS; STRUCTURE OF THE BOOK; Merck: Staying the Course; INTRODUCTION; FOCUSING ON PATIENTS AND THE LONG TERM; ETHICS RESOURCE CENTERS; INTERNAL ETHICAL PRACTICES; ASSESSING THE IMPACT; BENEFITS OF AN ETHICAL APPROACH; ETHICAL ISSUES; DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY
CLINICAL TRIALS AND PUBLICATION OF RESULTSWHAT DRUGS TO DEVELOP; CHALLENGES FOR THE FUTURE; Genzyme: Putting Patients First; INTRODUCTION; PUTTING THE PATIENT FIRST: GENZYMEÌS APPROACH TO ETHICAL ISSUES; ETHICAL ISSUES; ETHICAL MECHANISMS; SUSTAINING THE GENZYME CULTURE; CONCLUSION; Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values; INTRODUCTION; MILLENNIUM PHARMACEUTICALS INC.; INSTITUTIONALIZING CORE VALUES AND ETHICS; ETHICS EDUCATION PROGRAMS; IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS; PRESERVING A FOCUS ON CORE VALUES; THE FUTURE Maxim Pharmaceuticals (A): Internal and External DialoguesAN UNUSUAL BIOTECH LEADER; THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY; COMPANY HISTORY; EMBEDDING CORE VALUES; MECHANISMS FOR EMBEDDING CORE VALUES; BUILDING A SUCCESSFUL GLOBAL BOARD; ANNUAL STRATEGIC RETREAT; DEALING WITH ETHICAL ISSUES; MAXIM PHARMACEUTICALS (B); Diversa Inc.: Ethical Issues in Bioprospecting Partnerships; FROM BIOPIRACY TO BIOPROSPECTING; THE COMPANY; THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS; DIVERSAÌS BIODIVERSITY COLLABORATIONS; PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS ETHICAL DECISION MAKINGTOWARD THE FUTURE; DIVERSA INC. (B); DIVERSA INC. (C); DIVERSA INC. (D); Pipeline Biotech A/S: Competing Regulatory Regimes for Laboratory Animal Experiments; INTRODUCTION; COMPANY HISTORY; BUSINESS MODEL AND ETHICAL APPROACH; EMPOWERING THE WORKFORCE; ETHICAL ISSUES AT PIPELINE; CONCLUSION; TGN Biotech: A Start-Up with Ethical Roots; WHAT NOW?; TGN BIOTECH; TGNÌS MARKET; SEMENESISTM; WHY PIGS AND WHY SEMEN?; THE ETHICAL ISSUES; MECHANISMS FOR A TRANSPARENT PROCESS; FUTURE POSSIBILITIES; WHAT NEXT?; Interleukin Genetics and Alticor: An Unlikely Partnership; INTRODUCTION COMPANY ORIGINSEXPLORING THE ETHICS OF GENETIC TESTING; FAILED EFFORTS TO BUILD A PERSONALIZED MEDICINE BUSINESS; PUTTING ETHICS EXPERTS IN CHARGE; APPROACH TO ETHICAL ISSUES; PROPOSED ALTICOR DEAL; INTERLEUKIN GENETICS AND ALTICOR: AN UNUSUAL PARTNERSHIP; CREATING AN ETHICAL APPROACH TO NUTRIGENOMICS; Sciona Ltd.: A Pioneer in Nutrigenomics: The Path to Consumer Acceptance; INTRODUCTION; BACKGROUND; PRODUCT LAUNCH; ETHICAL CONSIDERATIONS; THE CASE FOR ETHICS; APPLICATION TO THE HUMAN GENETICS COMMISSION; PUBLIC OPPOSITION; RESULTS; THE HGC RECOMMENDATIONS; TOWARD THE FUTURE Affymetrix, Inc.: Using Corporate Ethics Advice |
| Record Nr. | UNINA-9910784648603321 |
| Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bioindustry ethics / / David L. Finegold ... [et al.]
| Bioindustry ethics / / David L. Finegold ... [et al.] |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 |
| Descrizione fisica | 1 online resource (384 p.) |
| Disciplina |
174/.96606
174.96606 |
| Altri autori (Persone) | FinegoldDavid |
| Soggetto topico |
Biotechnology industries - Moral and ethical aspects
Pharmaceutical industry - Moral and ethical aspects Business ethics - Moral and ethical aspects |
| ISBN |
1-281-00533-9
9786611005337 0-08-049251-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
BIOINDUSTRY ETHICS; BIOINDUSTRY ETHICS; Contents; Research Team; Preface; Acknowledgments; Introduction; ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES; WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS?; ETHICISTS AND THE BIOSCIENCE INDUSTRY; A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS; STRUCTURE OF THE BOOK; Merck: Staying the Course; INTRODUCTION; FOCUSING ON PATIENTS AND THE LONG TERM; ETHICS RESOURCE CENTERS; INTERNAL ETHICAL PRACTICES; ASSESSING THE IMPACT; BENEFITS OF AN ETHICAL APPROACH; ETHICAL ISSUES; DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY
CLINICAL TRIALS AND PUBLICATION OF RESULTSWHAT DRUGS TO DEVELOP; CHALLENGES FOR THE FUTURE; Genzyme: Putting Patients First; INTRODUCTION; PUTTING THE PATIENT FIRST: GENZYMEÌS APPROACH TO ETHICAL ISSUES; ETHICAL ISSUES; ETHICAL MECHANISMS; SUSTAINING THE GENZYME CULTURE; CONCLUSION; Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values; INTRODUCTION; MILLENNIUM PHARMACEUTICALS INC.; INSTITUTIONALIZING CORE VALUES AND ETHICS; ETHICS EDUCATION PROGRAMS; IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS; PRESERVING A FOCUS ON CORE VALUES; THE FUTURE Maxim Pharmaceuticals (A): Internal and External DialoguesAN UNUSUAL BIOTECH LEADER; THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY; COMPANY HISTORY; EMBEDDING CORE VALUES; MECHANISMS FOR EMBEDDING CORE VALUES; BUILDING A SUCCESSFUL GLOBAL BOARD; ANNUAL STRATEGIC RETREAT; DEALING WITH ETHICAL ISSUES; MAXIM PHARMACEUTICALS (B); Diversa Inc.: Ethical Issues in Bioprospecting Partnerships; FROM BIOPIRACY TO BIOPROSPECTING; THE COMPANY; THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS; DIVERSAÌS BIODIVERSITY COLLABORATIONS; PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS ETHICAL DECISION MAKINGTOWARD THE FUTURE; DIVERSA INC. (B); DIVERSA INC. (C); DIVERSA INC. (D); Pipeline Biotech A/S: Competing Regulatory Regimes for Laboratory Animal Experiments; INTRODUCTION; COMPANY HISTORY; BUSINESS MODEL AND ETHICAL APPROACH; EMPOWERING THE WORKFORCE; ETHICAL ISSUES AT PIPELINE; CONCLUSION; TGN Biotech: A Start-Up with Ethical Roots; WHAT NOW?; TGN BIOTECH; TGNÌS MARKET; SEMENESISTM; WHY PIGS AND WHY SEMEN?; THE ETHICAL ISSUES; MECHANISMS FOR A TRANSPARENT PROCESS; FUTURE POSSIBILITIES; WHAT NEXT?; Interleukin Genetics and Alticor: An Unlikely Partnership; INTRODUCTION COMPANY ORIGINSEXPLORING THE ETHICS OF GENETIC TESTING; FAILED EFFORTS TO BUILD A PERSONALIZED MEDICINE BUSINESS; PUTTING ETHICS EXPERTS IN CHARGE; APPROACH TO ETHICAL ISSUES; PROPOSED ALTICOR DEAL; INTERLEUKIN GENETICS AND ALTICOR: AN UNUSUAL PARTNERSHIP; CREATING AN ETHICAL APPROACH TO NUTRIGENOMICS; Sciona Ltd.: A Pioneer in Nutrigenomics: The Path to Consumer Acceptance; INTRODUCTION; BACKGROUND; PRODUCT LAUNCH; ETHICAL CONSIDERATIONS; THE CASE FOR ETHICS; APPLICATION TO THE HUMAN GENETICS COMMISSION; PUBLIC OPPOSITION; RESULTS; THE HGC RECOMMENDATIONS; TOWARD THE FUTURE Affymetrix, Inc.: Using Corporate Ethics Advice |
| Record Nr. | UNINA-9910809111003321 |
| Amsterdam ; ; Boston, : Elsevier Academic Press, c2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biotechnology and the human good [[electronic resource] /] / C. Ben Mitchell ... [et al.]
| Biotechnology and the human good [[electronic resource] /] / C. Ben Mitchell ... [et al.] |
| Pubbl/distr/stampa | Washington, D.C., : Georgetown University Press, c2006 |
| Descrizione fisica | 1 online resource (225 p.) |
| Disciplina | 174/.96606 |
| Altri autori (Persone) | MitchellC. Ben |
| Soggetto topico |
Biotechnology - Moral and ethical aspects
Medical ethics Values |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-58901-276-3
1-4356-2738-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The rapidly changing world of biotechnology -- Humanity and the technological narrative -- Biotechnology and competing worldviews -- Biotechnology and human dignity -- Biotechnology and the quest for control -- Biotechnology, human enhancement, and the ends of medicine. |
| Record Nr. | UNINA-9910452174503321 |
| Washington, D.C., : Georgetown University Press, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biotechnology and the human good [[electronic resource] /] / C. Ben Mitchell ... [et al.]
| Biotechnology and the human good [[electronic resource] /] / C. Ben Mitchell ... [et al.] |
| Pubbl/distr/stampa | Washington, D.C., : Georgetown University Press, c2006 |
| Descrizione fisica | 1 online resource (225 p.) |
| Disciplina | 174/.96606 |
| Altri autori (Persone) | MitchellC. Ben |
| Soggetto topico |
Biotechnology - Moral and ethical aspects
Medical ethics Values |
| ISBN |
1-58901-276-3
1-4356-2738-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The rapidly changing world of biotechnology -- Humanity and the technological narrative -- Biotechnology and competing worldviews -- Biotechnology and human dignity -- Biotechnology and the quest for control -- Biotechnology, human enhancement, and the ends of medicine. |
| Record Nr. | UNINA-9910778335103321 |
| Washington, D.C., : Georgetown University Press, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biotechnology and the human good / / C. Ben Mitchell ... [et al.]
| Biotechnology and the human good / / C. Ben Mitchell ... [et al.] |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Washington, D.C., : Georgetown University Press, c2006 |
| Descrizione fisica | 1 online resource (225 p.) |
| Disciplina |
174/.96606
174.96606 |
| Altri autori (Persone) | MitchellC. Ben |
| Soggetto topico |
Biotechnology - Moral and ethical aspects
Medical ethics Values |
| ISBN |
1-58901-276-3
1-4356-2738-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The rapidly changing world of biotechnology -- Humanity and the technological narrative -- Biotechnology and competing worldviews -- Biotechnology and human dignity -- Biotechnology and the quest for control -- Biotechnology, human enhancement, and the ends of medicine. |
| Record Nr. | UNINA-9910815319303321 |
| Washington, D.C., : Georgetown University Press, c2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Guiding Icarus [[electronic resource] ] : merging bioethics with corporate interests / / Rahul K. Dhanda ; foreword by Philip R. Reilly
| Guiding Icarus [[electronic resource] ] : merging bioethics with corporate interests / / Rahul K. Dhanda ; foreword by Philip R. Reilly |
| Autore | Dhanda Rahul K |
| Pubbl/distr/stampa | New York, : John Wiley & Sons, c2002 |
| Descrizione fisica | 1 online resource (298 p.) |
| Disciplina |
174.957
174/.96606 |
| Soggetto topico |
Biotechnology industries
Biotechnology - Moral and ethical aspects |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-36674-5
9786610366743 0-471-46132-6 0-471-22483-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
GUIDING ICARUS; CONTENTS; Foreword; Preface; Acknowledgments; 1 Introduction; 2 Genetically Modified Foods; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations; 3 DNA Data Banking; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations; 4 Personalized Medicine; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations; 5 Stem Cells; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations
6 ConclusionGlossary; Suggested Reading; Index |
| Record Nr. | UNINA-9910143224603321 |
Dhanda Rahul K
|
||
| New York, : John Wiley & Sons, c2002 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Guiding Icarus [[electronic resource] ] : merging bioethics with corporate interests / / Rahul K. Dhanda ; foreword by Philip R. Reilly
| Guiding Icarus [[electronic resource] ] : merging bioethics with corporate interests / / Rahul K. Dhanda ; foreword by Philip R. Reilly |
| Autore | Dhanda Rahul K |
| Pubbl/distr/stampa | New York, : John Wiley & Sons, c2002 |
| Descrizione fisica | 1 online resource (298 p.) |
| Disciplina |
174.957
174/.96606 |
| Soggetto topico |
Biotechnology industries
Biotechnology - Moral and ethical aspects |
| ISBN |
1-280-36674-5
9786610366743 0-471-46132-6 0-471-22483-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
GUIDING ICARUS; CONTENTS; Foreword; Preface; Acknowledgments; 1 Introduction; 2 Genetically Modified Foods; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations; 3 DNA Data Banking; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations; 4 Personalized Medicine; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations; 5 Stem Cells; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations
6 ConclusionGlossary; Suggested Reading; Index |
| Record Nr. | UNINA-9910830685103321 |
|
Dhanda Rahul K
|
||
| New York, : John Wiley & Sons, c2002 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Guiding Icarus [[electronic resource] ] : merging bioethics with corporate interests / / Rahul K. Dhanda ; foreword by Philip R. Reilly
| Guiding Icarus [[electronic resource] ] : merging bioethics with corporate interests / / Rahul K. Dhanda ; foreword by Philip R. Reilly |
| Autore | Dhanda Rahul K |
| Pubbl/distr/stampa | New York, : John Wiley & Sons, c2002 |
| Descrizione fisica | 1 online resource (298 p.) |
| Disciplina |
174.957
174/.96606 |
| Soggetto topico |
Biotechnology industries
Biotechnology - Moral and ethical aspects |
| ISBN |
1-280-36674-5
9786610366743 0-471-46132-6 0-471-22483-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
GUIDING ICARUS; CONTENTS; Foreword; Preface; Acknowledgments; 1 Introduction; 2 Genetically Modified Foods; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations; 3 DNA Data Banking; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations; 4 Personalized Medicine; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations; 5 Stem Cells; I. Executive Summary; II. The Science; III. The Benefits; IV. The Issues; V. Industry; VI. Recommendations
6 ConclusionGlossary; Suggested Reading; Index |
| Record Nr. | UNINA-9910841068503321 |
|
Dhanda Rahul K
|
||
| New York, : John Wiley & Sons, c2002 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||